IRIS Accounts Production v24.3.2.46 05916269 Board of Directors 1.4.23 31.3.24 31.3.24 false true false false false true false Ordinary A 1.00000 Ordinary B 1.00000 Ordinary C 1.00000 Ordinary D 1.00000 Ordinary E 1.00000 18118 1901 106860 126324 124978 110107 18118 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh059162692023-03-31059162692024-03-31059162692023-04-012024-03-31059162692022-03-31059162692022-04-012023-03-31059162692023-03-3105916269ns15:EnglandWales2023-04-012024-03-3105916269ns14:PoundSterling2023-04-012024-03-3105916269ns10:Director12023-04-012024-03-3105916269ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3105916269ns10:SmallEntities2023-04-012024-03-3105916269ns10:AuditExemptWithAccountantsReport2023-04-012024-03-3105916269ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3105916269ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3105916269ns10:FullAccounts2023-04-012024-03-310591626912023-04-012024-03-3105916269ns10:OrdinaryShareClass12023-04-012024-03-3105916269ns10:OrdinaryShareClass22023-04-012024-03-3105916269ns10:OrdinaryShareClass32023-04-012024-03-3105916269ns10:OrdinaryShareClass42023-04-012024-03-3105916269ns10:OrdinaryShareClass52023-04-012024-03-3105916269ns10:Director2422023-03-3105916269ns10:Director2422022-03-3105916269ns10:Director2422023-04-012024-03-3105916269ns10:Director2422022-04-012023-03-3105916269ns10:Director2422023-03-3105916269ns10:Director22023-04-012024-03-3105916269ns10:CompanySecretary12023-04-012024-03-3105916269ns10:RegisteredOffice2023-04-012024-03-3105916269ns5:CurrentFinancialInstruments2024-03-3105916269ns5:CurrentFinancialInstruments2023-03-3105916269ns5:Non-currentFinancialInstruments2024-03-3105916269ns5:Non-currentFinancialInstruments2023-03-3105916269ns5:ShareCapital2024-03-3105916269ns5:ShareCapital2023-03-3105916269ns5:RetainedEarningsAccumulatedLosses2024-03-3105916269ns5:RetainedEarningsAccumulatedLosses2023-03-3105916269ns5:NetGoodwill2023-04-012024-03-3105916269ns5:NetGoodwill2023-03-3105916269ns5:NetGoodwill2024-03-3105916269ns5:NetGoodwill2023-03-3105916269ns5:PlantMachinery2023-03-3105916269ns5:PlantMachinery2023-04-012024-03-3105916269ns5:PlantMachinery2024-03-3105916269ns5:PlantMachinery2023-03-3105916269ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3105916269ns5:WithinOneYearns5:CurrentFinancialInstruments2023-03-3105916269ns10:OrdinaryShareClass12024-03-3105916269ns10:OrdinaryShareClass22024-03-3105916269ns10:OrdinaryShareClass32024-03-3105916269ns10:OrdinaryShareClass42024-03-3105916269ns10:OrdinaryShareClass52024-03-31059162691ns10:Director12023-03-31059162691ns10:Director12022-03-31059162691ns10:Director12023-04-012024-03-31059162691ns10:Director12022-04-012023-03-31059162691ns10:Director12024-03-31059162691ns10:Director12023-03-31
REGISTERED NUMBER: 05916269 (England and Wales)






















Unaudited Financial Statements

for the Year Ended 31 March 2024

for

F2 Clinical Limited

F2 Clinical Limited (Registered number: 05916269)






Contents of the Financial Statements
for the year ended 31 March 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Chartered Accountants' Report 8

F2 Clinical Limited

Company Information
for the year ended 31 March 2024







DIRECTORS: Dr H L Fowler
E D Fowler





SECRETARY: E D Fowler





REGISTERED OFFICE: Dalton House
60 Windsor Avenue
London
SW19 2RR





REGISTERED NUMBER: 05916269 (England and Wales)





ACCOUNTANTS: Bennett Brooks & Co Limited
Chartered Accountants
St George's Court
Winnington Avenue
Northwich
Cheshire
CW8 4EE

F2 Clinical Limited (Registered number: 05916269)

Balance Sheet
31 March 2024

2024 2023
as restated
Notes £ £
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 5,393 12,902
5,393 12,902

CURRENT ASSETS
Debtors 6 348,450 387,677
Cash at bank 82,444 28,951
430,894 416,628
CREDITORS
Amounts falling due within one year 7 (276,979 ) (277,826 )
NET CURRENT ASSETS 153,915 138,802
TOTAL ASSETS LESS CURRENT
LIABILITIES

159,308

151,704

CREDITORS
Amounts falling due after more than one year 8 (19,898 ) (29,923 )
NET ASSETS 139,410 121,781

CAPITAL AND RESERVES
Called up share capital 9 110 110
Retained earnings 139,300 121,671
SHAREHOLDERS' FUNDS 139,410 121,781

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

F2 Clinical Limited (Registered number: 05916269)

Balance Sheet - continued
31 March 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 26 March 2025 and were signed on its behalf by:





Dr H L Fowler - Director


F2 Clinical Limited (Registered number: 05916269)

Notes to the Financial Statements
for the year ended 31 March 2024

1. STATUTORY INFORMATION

F2 Clinical Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The company has adopted the FRS 102 accounting policies and principles on a consistent basis from the date of transition. The principal policies are set out below:

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2006 has been fully amortised.

Tangible fixed assets
Tangible fixed assets are stated at cost less accumulated depreciation. Cost includes the original purchase price of the asset and the costs attributable to bringing the asset to its working condition for its intended use.

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost, less estimated residual value, of each asset on a systematic basis over its expected useful life as follows:

Fixtures and fittings- 20% on cost
Motor vehicles- 20% on cost
Computer equipment- 33% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all material timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

F2 Clinical Limited (Registered number: 05916269)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

2. ACCOUNTING POLICIES - continued

Share capital
Ordinary shares are classed as equity.

Short term debtors and creditors
Short term debtors and creditors with no stated interest rate are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account.

Cash and cash equivalents
Cash and cash equivalents includes cash in hand, cash held with banks and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Loans and borrowings
Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£
COST
At 1 April 2023
and 31 March 2024 124,000
AMORTISATION
At 1 April 2023
and 31 March 2024 124,000
NET BOOK VALUE
At 31 March 2024 -
At 31 March 2023 -

F2 Clinical Limited (Registered number: 05916269)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£
COST
At 1 April 2023 68,102
Additions 864
Disposals (8,937 )
At 31 March 2024 60,029
DEPRECIATION
At 1 April 2023 55,200
Charge for year 2,657
Eliminated on disposal (3,221 )
At 31 March 2024 54,636
NET BOOK VALUE
At 31 March 2024 5,393
At 31 March 2023 12,902

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
as restated
£ £
Trade debtors 221,691 283,600
Other debtors 126,759 104,077
348,450 387,677

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
as restated
£ £
Bank loans and overdrafts 10,015 9,768
Trade creditors 33,283 42,846
Taxation and social security 56,677 39,384
Other creditors 177,004 185,828
276,979 277,826

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2024 2023
as restated
£ £
Bank loans 19,898 29,923

F2 Clinical Limited (Registered number: 05916269)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: as restated
£ £
80 Ordinary A £1 80 80
20 Ordinary B £1 20 20
2 Ordinary C £1 2 2
4 Ordinary D £1 4 4
4 Ordinary E £1 4 4
110 110

10. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31 March 2024 and 31 March 2023:

2024 2023
as restated
£ £
Dr H L Fowler and E D Fowler
Balance outstanding at start of year 18,118 1,901
Amounts advanced 106,860 126,324
Amounts repaid (124,978 ) (110,107 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year - 18,118

This amount attracts no interest and is repayable on demand.

11. RELATED PARTY DISCLOSURES

Included in other debtors is £85,005 (2023 - £44,042) owed from companies of which Dr H L Fowler and E D Fowler are directors and shareholders.

This amount attracts no interest and is repayable on demand.

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
F2 Clinical Limited

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of F2 Clinical Limited for the year ended 31 March 2024 which comprise the Income Statement, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of F2 Clinical Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of F2 Clinical Limited and state those matters that we have agreed to state to the Board of Directors of F2 Clinical Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than F2 Clinical Limited and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that F2 Clinical Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of F2 Clinical Limited. You consider that F2 Clinical Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of F2 Clinical Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Bennett Brooks & Co Limited
Chartered Accountants
St George's Court
Winnington Avenue
Northwich
Cheshire
CW8 4EE


26 March 2025